Denise joined Seventure Partners, a European Leader in Venture Capital, in 2015 as an Investment Advisor to the Life Sciences Team and is focused specifically on Global Human Microbiome investment opportunities. Prior to joining Seventure, Denise was head of her research team at the World-renowned Rowett Institute, University of Aberdeen, where she acquired over 20 years’ experience in gut microbiology and immunology. She was CEO of GT Biologics, one of the first translational spinouts, developing Innovative Microbiome-based Therapies acquired by 4D Pharma plc, and is an inventor on numerous microbiome patents.